Ambrisentan/tadalafil - GlaxoSmithKline

Drug Profile

Ambrisentan/tadalafil - GlaxoSmithKline

Alternative Names: Tadalafil/ambrisentan

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Hammersmith Medicines Research
  • Class Antihypertensives; Benzodioxoles; Carbolines; Indoles; Phenylpropionates; Pyridazines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pulmonary hypertension

Most Recent Events

  • 04 Aug 2017 GlaxoSmithKline completes a phase I trial in Pulmonary hypertension (In volunteers) in United Kingdom (PO) (NCT02688387)
  • 01 Mar 2016 Phase-I clinical trials in Pulmonary hypertension (In volunteers) in United Kingdom (PO) (NCT02688387)
  • 18 Feb 2016 GlaxoSmithKline plans a phase I pharmacokinetics trial in Healthy volunteers in United Kingdom (PO) (NCT02688387)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top